

Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Fezolinetant

August 2024

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Fezolinetant

Dosage Form: Tablet

Route: Oral

Strength: 45 mg

Recommended Study: One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fasting
Design: Single-dose, two-treatment, two-period crossover in vivo
Strength: 45 mg
Subjects: Healthy non-pregnant, non-lactating females
Additional comments: Enrollment of postmenopausal females is encouraged. Subjects should not be current smokers.

Analyte to measure: Fezolinetant in plasma

Bioequivalence based on (90% CI): Fezolinetant

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA’s Dissolution Methods database, <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Conduct comparative dissolution testing on 12 dosage units each of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.

Document History: Recommended August 2024

Unique Agency Identifier: PSG_216578